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A strategy for increasing the efficiency of protein crystallization/structure determination with
mass spectrometry has been developed. This approach combines insights from limited
proteolysis/mass spectrometry and crystallization via in situ proteolysis. The procedure seeks
to identify protease-resistant polypeptide chain segments from purified proteins on the
time-scale of crystal formation, and subsequently crystallizing the target protein in the
presence of the optimal protease at the right relative concentration. We report our experience
with 10 proteins of unknown structure, two of which yielded high-resolution X-ray structures.
The advantage of this approach comes from its ability to select only those structure
determination candidates that are likely to benefit from application of in situ proteolysis, using
conditions most likely to result in formation of a stable proteolytic digestion product suitable
for crystallization. (J Am Soc Mass Spectrom 2010, 21, 1795–1801) © 2010 American Society
for Mass SpectrometryKnowledge of protein’s three-dimensional (3-D)structure is often critical for understandingfunction. Various techniques, including X-ray
crystallography, nuclear magnetic resonance (NMR),
mass spectrometry (MS), circular dichroism (CD), Fourier-
transform (FT) infrared (IR), Raman, ultraviolet (UV)-
visible absorption and fluorescence spectroscopies, are
used for protein analyses [1, 2]. Among these methods,
X-ray crystallography has surpassed all other tech-
niques in revealing structural information at atomic
resolution for macromolecules, thereby contributing the
majority of protein structures to the Protein Data Bank
(www.pdb.org) [3]. Although productivity in this field
continues to accelerate, overall failure rates in determin-
ing the structure of a given target remain high [4–6].
Success depends both on the stability and solubility of
the target protein and on surveying appropriate crys-
tallization conditions. As a result, protein engineering
has emerged as an important means of improving
protein physicochemical properties, which can render
them more amenable to crystallization [7].
Since the development of MALDI and ESI modes of
ionization for macromolecules [8–10], MS has become
an essential tool for protein crystallographers. Within
structural proteomics, MS is now routinely used for
sample quality control, crystal content verification,
analysis of selenomethionine incorporation and post-
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doi:10.1016/j.jasms.2010.06.015translational modifications, and identification of oli-
gomerization states [11]. MS is also frequently used to
identify stable domains within larger proteins [12–17].
The power of limited proteolysis/mass spectrometry
(LPMS) to identify the N- and C-termini of stable
domains is well documented and is frequently used to
support design of expression constructs that produce
proteins suitable for crystallization. Recently, in situ
proteolysis has emerged as a productive strategy for
modifying proteins that otherwise prove recalcitrant to
crystallization [4, 18]. In favorable cases, one or both of
these established proteolysis-based approaches can im-
prove the chances of obtaining diffraction quality crys-
tals. However, there are many proteins that do not
succumb readily to either strategy, and there is a need
for a more refined approach to the problem.
Herein, we describe a simple, generic protocol for
identifying the optimum protease:protein ratios to gen-
erate stable protein domains on a time scale comparable
to the duration of crystallization trials. The procedure is
cost-effective and robust. MS provides a rapid/straight-
forward read out of the extent of polypeptide chain
cleavage and the long-term stability of protein domains
generated by limited proteolysis. The utility of this
approach was tested by applying it to a representative
set of 10 protein targets of unknown structure. Our
protocol yielded diffraction quality crystals in four
cases, leading to determination of two novel high-
resolution structures. Importantly, it also identified four
targets as being unsuitable for a proteolytic approach to
protein engineering.
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Cloning, Expression, and Purification of Proteins
Genes encoding the 10 protein targets of interest were
cloned from genomic DNA or from codon-optimized
synthetic templates. The desired amino acid boundaries
were PCR amplified and the purified PCR products
were subsequently TOPO (Invitrogen, Carlsbad, USA)
cloned into pSGX3, a derivative of pET26b(), that
expresses protein with a noncleavable C-terminal hexa
histidine tag. The resulting plasmids were transformed
into BL21(DE3)-Condon RIL (Invitrogen) cells for over-
expression. Se-Met protein production was carried out at
22 °C in 1L of high yield (HY) media (Orion Enterprises,
Inc, Northbrook, IL, USA) containing 50 g/mL of
kanamycin and 35 g/mL of chloramphenicol. Protein
expression was induced by addition of 0.4 mM IPTG.
Cells were harvested after 21 h by centrifugation at 4 °C.
For purification, the E. coli cell pellets were resus-
pended in cold buffer [20 mM Tris HCl pH 8.0, 500 mM
NaCl, 25 mM imidazole, and 0.1% (vol/vol) Tween20]
and were lysed via sonication. Cellular debris was
removed by centrifugation at 4 °C and the decanted
supernatant from each sample was applied to a 5 mL
HisTrap-HP column (GE Health Care, Piscataway, NJ,
USA) charged with nickel and pre-equilibrated with 20
mM Tris HCl pH 8.0, 500 mM NaCl, 10% (vol/vol)
glycerol, and 25 mM imidazole. Bound samples were
washed with 5 column volumes (CV) of 20 mM Tris
HCl pH 8.0, 500 mM NaCl, 10% (vol/vol) glycerol, and
40 mM imidazole and subsequently eluted with 2 CVs
of the same buffer, with an imidazole concentration of
250 mM. Eluted proteins were further purified using a
120 mL Superdex 200 size-exclusion column pre-
equilibrated with 10 mM HEPES pH 7.5, 150 mM NaCl,
10% (vol/vol) glycerol, and 5 mM DTT (protein storage
buffer). SDS-PAGE analysis showed greater than 95%
purity and protein fractions corresponding to the sym-
metric portion of the size exclusion chromatography
profile were pooled for concentration using AMICON
(Millipore, Billerica, MA, USA) spin filters. Concen-
trated protein aliquots were flash frozen using liquid
nitrogen and stored at 80 °C.
Protein Characterization
Matrix assisted laser desorption/ionization (MALDI)-MS
(Voyager, DE-RP; Applied Biosystems, Foster City, CA,
USA) and a liquid chromatography (LC)-electrospray
ionization (ESI) mass spectrometer equipped with a
quadrupole mass analyzer (API 150EX; Applied Biosys-
tems) were used to determine the molecular masses of
all protein samples. This information was required to
assess both purity and chemical homogeneity, and to
compare measured molecular masses to the calculated
molecular masses derived from the expected proteinsequence. In situ proteolysis mass spectrometry exper-
iments were performed on protein samples with greater
than 95% purity.
Proteolytic Digestion and Mass Spectrometry
Ten L of each target protein (2 mg/mL concentra-
tion) was independently incubated with three proteases
(Proteinase K, Subtilisin and Chymotrypsin; Roche,
Indianapolis, IN, USA) at room temperature over 9 days
(which is comparable to the duration of crystallization
trials). Four different protease-to-target ratios were
used, including 1:5000, 1:10,000, 1:50,000, and 1:100000.
Proteolytic reactions were conducted in protein storage
buffer. Stock solutions of proteases were also prepared
in protein storage buffer. Reactions were quenched at
predetermined intervals by aliquoting 1 L of reaction
mixture into 1 L of 5% TFA. Extent of proteolysis was
monitored by mass analysis using MALDI-MS. A mod-
ified “thin-layer” method [19] was used for sample
preparation. To improve the reproducibility of the
sample analysis, saturated -cyano-4-hydroxy-cinnamic
acid (HCCA) matrix solution was prepared by dissolu-
tion into a mixture of formic acid, water, and isopro-
panol (a ratio of 3:1:2, respectively). Matrix solution
was warmed in a boiling water bath for 2 min and
maintained at 40 °C during sample preparation; 0.5
L of the protein digest was mixed with 9.5 L of
warm matrix solution, and 0.2 L of the final mixture
was used for spotting on pre-layered MALDI sample
plates.
MALDI-MS measurements were performed using a
Voyager DE-RP mass spectrometer equipped with a
pulsed N2 laser (  337 nm, pulse width 4 ns, fre-
quency 20 Hz). MALDI mass spectra were obtained in
positive linear mode by averaging the results of 300
individual laser shots. Thirty-six protease:protein di-
gests (derived from three protein samples) were spotted
on a MALDI-MS sample plate around a standard (for
calibration). Mass calibration was carried out with
carbonic anhydrase as an external standard (MW 29027
Da) using singly and doubly charged ionic species.
Mass error  0.1% was expected due to spatial distri-
bution and ignored because of subsequent ESI-MS
analysis (mass error 0.01%); this procedure permitted
more rapid analysis. MALDI-MS analysis was per-
formed on alternate days (up to 9 d) to monitor the
extent of protease digestion. No further mass analyses
were performed on protein samples showing complete
degradation and/or precipitation. If necessary, sites of
proteolytic cleavage were identified by more accurate
mass measurement using LC-ESI-MS. These measure-
ments were conducted at an ion spray voltage of 5500
V, source temperature of 300 °C, a focusing potential
of 250 V, and a scan range of 1100 to 1900 m/z. Protein
molecular masses were estimated using BioAnalyst
ver. 1.4.
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Protein samples were mixed with the appropriate
amount of protease and immediately subjected to crys-
tallization screening (0.3 L protein  0.3 L reservoir
solution) with the Classics, Classics II, and PEGs kits
(Qiagen, Valencia, CA, USA) using a Phoenix Liquid
Handling System (Art Robins, Sunnyvale, CA, USA) via
sitting drop vapor diffusion at 21 °C. On first examina-
tion of these initial crystallization experiments 24 h
later, there were significant numbers of crystalline hits
compared with the results of control experiments that
excluded proteases. Crystals obtained at various condi-
tions were flash frozen by direct immersion in liquid
nitrogen after cryo-protection via addition of 20% (vol/
vol) ethylene glycol. Diffraction data were recorded
using the LRL-CAT 31-ID beamline at the Advanced
Photon Source (APS), and processed with MOSFLM
[20] and SCALA [21] (Collaborative Computing Project
Number 4, 1994).
Results and Discussion
The observations described in this paper and the collec-
tive experiences within structural biology as a disci-
pline underscore the challenges of working with full
Figure 1. Schematic view of protein characteri
structure that readily forms crystals; (b) flexibl
crystal formation; (c) extra domain and disorder
domain of interest; (d) disordered loop tha
(e) interacting domains that must be re-expres
(f) special case of a multi-domain protein, in wh
modified protein that formed a compact arrangement olength proteins. In favorable cases, proteins such as en-
zymes secreted by the exocrine pancreas [22] that have
evolved to be biochemically active at extremes of pH, ionic
strength, presence of proteases, etc. tend to have compact
globular structures. Such enzymes were among the first
proteins to be successfully studied by X-ray crystallogra-
phy. Frequently, their inherently stable tertiary structures
(Figure 1a) support crystallization without the need for
protein engineering. At the NYSGXRC, we have had
similar experiences with many members of the enolase
superfamily. These proteins proved to be particularly
well suited to crystallization with standard crystalliza-
tion protocols [23] resulting in a success rate of 57% in
going from homogenous, soluble purified protein to a
3D structure (http://pepcdb.pdb.org). Many proteins
of interest to structural biologists, particularly those
from eukaryotes, do not behave in this fashion. Figure
1b to e illustrate some of the more challenging target
categories for which protein engineering is often re-
quired to identify and expunge flexible polypeptide
chain segments that can impede crystal formation.
To overcome these challenges, we have combined
both LPMS and in situ proteolysis strategies to identify
the optimal protease concentration yielding a stably
truncated form of the target protein. Proteolysis is
that complicate crystal formation. (a) Compact
and/or C-termini that need to be removed for
op that must be removed to form crystals of the
st be removed to crystallize two domains;
r re-purified after excising a disordered loop;





ich uf domains amenable to X-ray analysis [26].
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polypeptide chain; it may be at the N-terminus and/or
the C-terminus or within solvent-exposed loop(s) sepa-
rating globular regions of the polypeptide chain. MS
identified combinations of protease(s) and protease/
concentration(s) can be used for in situ proteolysis
crystallization trials to increase the likelihood of suc-
cessful structure determination. We describe our expe-
rience using in situ proteolysis guided by prior MS
analyses to provide a rational means of identifying a
target compatible protease and its optimal concentra-
Table 1. Mass Spectrometry aided in situ proteolysis of protein
Protein ID Chymotrypsin
15547 1/105 1/5  104 1/104 1/5  103 1/105 1/5
2 2 2 2 2





14771 1/105 1/5  104 1/104 1/5  103 1/105 1/5
2 2 2 2 2
CD CD CD CD CD
15101 1/105 1/5  104 1/104 1/5  103 1/105 1/5
2 2 2 2 2
ND ND SI SI SI
14639 1/105 1/5  104 1/104 1/5  103 1/105 1/5
2 2 2 2 2
ND ND ND ND SI
15527 1/105 1/5  104 1/104 1/5  103 1/105 1/5
2 2 2 2 2
ND ND SI SI ND
15546 1/105 1/5  104 1/104 1/5  103 1/105 1/5
2 2 2 2 2
SI SI SI SI SI
16279 1/105 1/5  104 1/104 1/5  103 1/105 1/5
2 2 2 2 2




A total of 12 protein:protease combinations gave stable homogenous
Three protein samples, which precipitated within 24 h were not used f
SH stable homogenous form of digested protein; SI heterogenous m
diffraction quality crystals; PDB  structure deposition; NC  no crysta
Targets used in this study: PID 15547, NYSGXRC-11030h, P24242: 3-33
10086f, Q71ZA7: 2-302/T189S; PID 14639, NYSGXRC-10057f, Q7WUJ6: 2-39
NYSGXRC-11029y, P0ACZ4: 2-204; PID 16279, NYSGXRC-11030w, O06987: 5tion for subsequent, directed in situ proteolysis crystal-
lization trials.
As part of the technology development activities
undertaken by the NIH-funded NYSGXRC structural
genomics consortium (New York SGX Research Center
for Structural Genomics, www.nysgxrc.org), 10 repre-
sentative protein targets of unknown structure were
selected for MS-in situ proteolysis experiments (Table 1).
Although all of these proteins could be purified to
homogeneity, none yielded crystals using our standard
crystallization protocol [23]. Each of these 10 proteins
had previously failed to produce diffraction quality crystals
inase K Subtilisin
04 1/104 1/5  103 1/105 1/5  104 1/104 1/5  103
2 2 2 2 2 2
SI SH ND ND SH CD
2 2
DQC DQC
04 1/104 1/5  103 1/105 1/5  104 1/104 1/5  103
2 2 2 2 2 2
CD CD CD CD CD CD
04 1/104 1/5  103 1/105 1/5  104 1/104 1/5  103
2 2 2 2 2 2
SH SH ND ND SI SI
2 2
NC NC
04 1/104 1/5  103 1/105 1/5  104 1/104 1/5  103
2 2 2 2 2 2
SI SI SI SI SI SI
04 1/104 1/5  103 1/105 1/5  104 1/104 1/5  103
2 2 2 2 2 2
SI SH ND ND SI SH
2 2
NC NC
04 1/104 1/5  103 1/105 1/5  104 1/104 1/5  103
2 2 2 2 2 2





04 1/104 1/5  103 1/105 1/5  104 1/104 1/5  103
2 2 2 2 2 2




s of digested product leading to two high resolution novel structures.
ther analysis and are not included in this table.
e of digested and undigested protein; CD complete digestion; DQC
ND  did not diffract.






























5; PI9/I309M; PID 15527, NYSGXRC-11020w, Q6G3E4: 23-374; PID 15546,
0-316.
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zymes at four different concentrations. In all, 12 differ-
ent combinations (protease  protease:protein concen-
tration ratios) were surveyed for each protein sample.
Cleavage products were analyzed by MALDI-MS to
identify the best protease and protease:protein ratio for
use in subsequent, directed in situ proteolysis crystalli-
zation trials. A schematic representation of the protocol
is provided in Figure 2. MALDI-MS is the method of
choice for molecular mass measurements because it pro-
vides rapid, reproducible, and easy-to-read mass spectra.
Moreover, this technique is compatible with various salts/
buffers used routinely in protein purification.
Figure 3a shows the MALDI mass spectrum of
one of our purified protein targets (an E. coli transcrip-
tional repressor, Genbank NP_417194, PSI TargetID
“NYSGXRC-11030h”). The predicted mass of the
protein plus the affinity purification tag (NYSGXRC
proteinID 15547) is 38362 Da (346 residues, including a
nonremovable C-terminal His tag). Within experimen-
tal error, the observed mass matches the predicted mass
derived from a sequence-verified expression plasmid.
Figure 3b and c show the MALDI mass spectra after
digesting the same sample with chymotrypsin at 1:5000
(protease:protein) ratio for one and nine days, respec-
tively. A stable domain of32 kDa molecular mass was
produced after 1 day of digestion (no further digestion
was observed over the following 8 d). Accurate mass
Figure 2. Protocol for mass spectrometry guid
determination.measurement using ESI-MS identified the precise N-
and C-termini of the chymotrypsin cleavage product. In
this particular case, the calculated mass was 31,913 Da.
The N-terminal 56 amino acids (comprising the DNA-
binding region) were removed, yielding a protease-
resistant 290 residue domain (residues 57-338 plus EG
and C-terminal His6 tag; predicted mass: 31,911 Da).
Similar cleavage patterns were observed for Subtilisin
and Proteinase K at protease:protein concentration ra-
tios of 1:10,000 and 1:5000, respectively. After identify-
ing the optimum protease/concentration combinations
(Table 1) that produced stable cleavage products, di-
rected in situ proteolysis crystallization trials were
performed. All three protease/concentration combina-
tions yielded crystals, with one leading to an X-ray struc-
ture determined at 2.45 Å resolution (PDB code: 3DBI).
The remaining nine combinations were not pursued be-
cause either the protein was not fully digested to form a
single stable cleavage product or it was completely
degraded.
Our strategy in surveying protease/concentration
combinations permitted efficient identification of a few
optimal combinations for the protein target that subse-
quently yielded crystals. In this particular case, the
presence of the N-terminal region appears to have
hindered crystallization of full-length protein. Appro-
priately chosen conditions for in situ proteolysis per-
situ proteolysis to obtain crystals for structureed in
1800 GHEYI ET AL. J Am Soc Mass Spectrom 2010, 21, 1795–1801mitted removal of this segment followed by successful
nucleation and formation of diffraction quality crystals.
Internal loop digestion can also yield diffraction
quality crystals [24, 25]. One of our 10 recalcitrant
protein targets succumbed following internal loop
cleavage followed by complete digestion of a small
C-terminal segment. The predicted mass of this target
(Genbank NP_416870, NYSGXRC-11029y, NYSGXRC
proteinID 15546) is 24004 Da. Figure 4a shows the intact
mass analysis of the full length protein before protease
addition. After 1 days of digestion with proteinase K
(1:10,000), two peaks were observed at 9.4 and 14.5 kDa
(Figure 4b). Thereafter, the polypeptide chain segment
corresponding to the peak at 9.4 kDa was degraded,
resulting in a single 14.5 kDa peak that resisted further
cleavage for 8 additional days (Figure 4c). Similar
findings were obtained with Subtilisin at a 1:5000
protease:protein ratio. Using ESI-MS, the stable portion
of the protein was identified as the N-terminal domain
comprising 135 amino acids; the C-terminal portion (79
amino acids) having been completely removed and then
Figure 3. MALDI mass spectra of an E. coli transcriptional
repressor, Genbank NP_417194, PSI TargetID “NYSGXRC-
11030h” (a) without addition of any protease; (b) after incubating
with chymotrypsin (1:5000) for 1 day; (c) after incubating with
chymotrypsin (1:5000) for 9 d. See Figure 1 for explanation of inset
cartoon.degraded. These two protease conditions were usedduring subsequent directed in situ proteolysis crystal-
lization trials and both these conditions yielded crys-
tals, one of which resulted in a crystal structure deter-
mined at 1.45 Å resolution (PDB code: 3F6C).
In situ proteolysis has previously been shown to be a
successful salvage technique for obtaining better quality
crystals [4, 18]. When pursuing high-throughput struc-
ture determination, however, choosing a single protease
and relative enzyme concentration may not be suffi-
cient. Table 1 documents that for a given target only a
few of the twelve surveyed protein:protease combina-
tions yielded stable, homogenous (SH) proteolysis
products that are suitable for subsequent crystallization
trials. The remaining protein:protease combinations
need not be examined further. Using the protocol
described in this paper, we were able to triage in situ
proteolysis crystallization conditions for each target,
thereby saving considerable futile efforts in the crystal-
lization laboratory. Moreover, four of our 10 structure
determination targets were shown to be unsuitable for
in situ proteolysis crystallization. Target NYSGXRC-
9269c, an amidohydrolase, (PID: 14771) was completely
degraded by each of the three proteases at all protease:
Figure 4. MALDI mass spectra of protein sample (Genbank
NP_416870, NYSGXRC-11029y, NYSGXRC proteinID 15546)
(a) without addition of any protease; (b) after incubating with
proteinase K (1:10,000) for 1 d; (c) after incubating with proteinase
K (1:10,000) for 9 d. See Figure 1 for explanation of inset cartoon.
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targets underwent massive precipitation within 24 h of
protease addition and failed to yield interpretable mass
spectra.
In summary, application of our strategy yielded two
novel protein structures at a total “cost” of 12 sets of
crystallization attempts on six apparently promising
targets. Brute force in situ proteolysis with the same
protease:protein combinations for all 10 targets would
have yielded the same two novel structures, at a 10-fold
higher total “cost” of 120 sets of crystallization trays.
Conclusions
To support high-throughput X-ray structure determina-
tion of proteins, our enzymatic digestion/mass spec-
trometry strategy permitted identification of optimal
combinations of protease and target protein for crystal-
lization via proteolysis/MS. Proteins tend to respond
differently to protease exposure based on their primary,
tertiary and quaternary structures. We have demon-
strated that identifying optimal experimental condi-
tions before directed in situ proteolysis crystallization
trials can significantly improve the efficiency of this
structure determination salvage pathway. Our protocol
rapidly identifies experimental conditions most likely
to produce a homogenous, stable protein species. This
approach not only eliminates need for recloning, ex-
pression, and purification (as with LPMS), but also
increases the likelihood of identifying conditions that
yield limited digests of challenging protein targets.
Finally, it can be used to identify proteins with intrin-
sically disordered regions that are largely or completely
digested in the presence of trace amounts of protease,
suggesting that alternative methods may be necessary
to determine their 3D structure.
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